Home | Emory University

Infectious Diseases Clinical Research Consortium (IDCRC)

Infectious Diseases Clinical Research Consortium

Slide 1:
Slide 2:
Slide 3:

The Infectious Diseases Clinical Research Consortium (IDCRC) and Vaccine and Treatment Evaluation Units (VTEUs) work in tandem with the National Institute of Allergy and Infectious Diseases (NIAID) as a coordinated national and global network of scientific experts working to develop and test vaccines and other therapies to combat infectious diseases.

Janssen Investigational COVID-19 Vaccine: Interim Analysis of Phase 3 Clinical Data Released

An investigational COVID-19 vaccine developed by Janssen Pharmaceuticals, and tested at VTEU sites, appears to be safe and effective at preventing moderate and severe COVID-19 in adults.

NIH News

COVID-19 Vaccine Appears Well-Tolerated and Effective in Developing Antibodies in Small Study of Older Adults

COVID-19 Prevention Network

The CoVPN was established by merging four existing NIAID-funded clinical trials networks: the HIV Vaccine Trials Network; the HIV Prevention Trials Network; the Infectious Diseases Clinical Research Consortium; and the AIDS Clinical Trials Group.

More about the CoVPN

COVID-19 Prevention Network launches two research studies evaluating monoclonal antibodies

IDCRC Sites Across the Nation

SUPPORT OF CLINICAL RESEARCH FOR 2019 NOVEL CORONAVIRUS (SARS-COV-2) & DISEASE (COVID-19)

The novel coronavirus 2019-nCoV, SARS-CoV-2, pandemic continues to expand and the IDCRC is working with NIAID to conduct clinical research into the treatment and prevention of infections (COVID-19) caused by this virus. What we know about COVID-19 and SARS-CoV-2 is constantly changing. To stay up-to-date on the most current information about how the epidemic is impacting the world, we recommend that you visit the following websites for reliable and accurate information.

View Resources

VTEU COVID-19 Trials

Analysis Demonstrates Effectiveness of LY-CoV555 Antibody in Preventing Symptomatic COVID-19

Researchers from the CoVPN and VTEU announced that the monoclonal antibody (mAb), LY-CoV555 (bamlanivimab), evaluated in a Phase III trial significantly reduces the risk of contracting symptomatic COVID-19 as well as reduces the clinical course of COVID-19 in study participants who did become symptomatic.

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination

Letter to the New England Journal of Medicine (NEJM) editor from NIAID, IDCRC and VTEU investigators

Gritstone Advances Second Generation COVID-19 Vaccine 'CORAL' Program

with Support from NIAID; Program has Potential to Protect Against Mutant Variants of SARS-CoV-2. A Phase 1 clinical trial, expected to be conducted through the NIAID-supported Infectious Diseases Clinical Research Consortium (IDCRC), is in development.

Regeneron reports positive interim data with REGEN-COV antibody cocktail used as passive vaccine to prevent COVID-19

Partcipating IDCRC Sites: New York University VTEU and Emory University VTEU Emory Children's Center - Vaccine Research Center

About

The IDCRC works through a flexible, sustaining structure to advance new countermeasures and approaches to product development, implement efficient clinical study/trial designs, and support exceptional career development and mentoring of future leaders in infectious diseases clinical research. The consortium's collective experience and access to diverse populations give it the ability to evaluate new vaccines and therapies for infectious diseases.

IDCRC Active & Completed Studies